Drugs / Tempol
Tempol
also known as
MBM-02 · 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl · MTS-01 · 4-oxypiperidol · NSC-142784 · SPJ-701 · Tanol · ZJ-701
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03680404 | Oct 2018 → Feb 2020 | vascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT03680638 | Sep 2016 → Oct 2017 | cardiovascular disorder, isoproterenol-mediated vasodilatation | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT01324141 | Mar 2011 → Apr 2015 | anal carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 23 trials | ||||||
| Phase 2 | NCT04874506 | Jun 2021 → Jan 2023 | glioblastoma | Matrix Biomed, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04876755 | May 2021 → Sep 2022 | prostate carcinoma | Matrix Biomed, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00801086 | Nov 2008 → Dec 2009 | alopecia | Mitos Pharmaceuticals | Unknown | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04337099 | — | prostate cancer | Matrix Biomed, Inc. | Available | No outcome recorded |
| — | NCT05491928 | — | metastatic malignant neoplasm | Matrix Biomed, Inc. | Available | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT06424756 Background | Jul 2024 → Mar 2030 expected | — | University of Georgia | Recruiting | No outcome recorded |
| Phase 2 | NCT03480971 Comparator | May 2019 → Jul 2025 overdue | cisplatin toxicity, mucositis, platinum-induced ototoxicity | Matrix Biomed, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04729595 Comparator | Sep 2021 → Sep 2022 | COVID-19 | Adamis Pharmaceuticals Corporation | Terminated | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tempol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00801086 ↗ |
| Known as | 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl | “MTS-01 (tempol, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) is a piperidine nitroxide known to act as a chemical radioprotector with selective protection of normal versus...” NCT01324141 ↗1“This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus.” NCT03680638 ↗ |
| Known as | 4-oxypiperidol | ChEMBL registry synonym — accepted as the source's own label CHEMBL607023 ↗ |
| Known as | MBM-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04874506 ↗ |
| Known as | MTS-01 | “MTS-01 (tempol, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) is a piperidine nitroxide known to act as a chemical radioprotector with selective protection of normal versus...” NCT01324141 ↗1“7% (w/v) Tempol alcohol-based gel (MTS-01)” NCT00801086 ↗ |
| Known as | NSC-142784 | ChEMBL registry synonym — accepted as the source's own label CHEMBL607023 ↗ |
| Known as | SPJ-701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL607023 ↗ |
| Known as | Tanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL607023 ↗ |
| Known as | ZJ-701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL607023 ↗ |
| Action | Inhibit | “MBM-02 is an HIF-1 and HIF-2 inhibitor that has shown in animal models to turn back on the apoptosis process (cell death) in cancer.” NCT04874506 ↗ |
| Modality | Small molecule | — CHEMBL607023 ↗ |
| Route | Topical | “a topical gel will be applied directly to the scalp” NCT00801086 ↗ |